Cardiovascular Diseases Clinical Trial
Official title:
NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease
The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial function.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | November 24, 2019 |
Est. primary completion date | September 24, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria:Qualified patients should have all 4 main criteria 1. Age 18-75 years of age for patients who regularly use NSAIDs. 2. Age 18-65 years of age for patients who do not regularly use NSAIDs 3. Able to give informed consent 4. Subjects with CVD or increased CV risk. Please see definitions for each criteria below: - Increased CV risk (Subjects should have at least 3 of the following) - > 55 years of age - Hypertension - Dyslipidemia (LDL > 160 mg/dL or HDL < 40 mg/dL in females and < 35 mg/dL in males or subjects currently receiving lipid lowering therapy as standard of care (i.e. statin drugs, prescription ? 3-acid ethyl esters, fibrates or prescription niacin [=1,000 mg/d]) - Family history of premature CV disease (MI, angina pectoris, heart failure, cardiac death or coronary revascularization, stroke, carotid endarterectomy, or other arterial surgery or angioplasty for atherosclerotic vascular disease in a parent, grandparent, or sibling with symptom onset or diagnosis before age 55 y for males and 65 y for females) - Current smoker - Left ventricular hypertrophy - Documented ankle brachial index of <0.9 - History of microalbuminuria, urine protein-creatinine ratio of >2 - CV disease (defined as one of the following): - Calcium score of >0 - = 50 % occlusion of a coronary artery by angiography - = 50 % occlusion of a carotid artery by angiography or ultrasound - History of stable angina - Symptomatic peripheral arterial disease - Prior MI, unstable angina, percutaneous coronary intervention, CABG, TIA, ischemic stroke, carotid endarterectomy, or other arterial surgery or angioplasty, which have occurred > 3 months prior to screening visit - Diabetes Mellitus type 1 or 2 (considered a CV disease equivalent). - Clinical diagnosis of rheumatoid arthritis, as determined by individual patient and physician, requiring daily treatment with NSAIDs. Exclusion Criteria: Subjects with any of the following criteria will be excluded from this study: 1. Unstable angina, MI, CVA, CABG <3 months from screening visit 2. Planned coronary, cerebrovascular, or peripheral revascularization 3. Undergone major surgery within 3 months prior to screening visit or has planned major surgery during the study period 4. Uncontrolled hypertension (SBP >190, DBP >100 mm Hg) during screening visit 5. Uncontrolled arrhythmia < 3 months from screening visit 6. NYHA class III-IV heart failure or if available, ejection fraction = 35 % 7. Within 6 months prior to screening visit, a history of ACS or hospitalization for heart failure 8. Oral corticosteroid, prednisone (or equivalent) > 20 mg daily 9. Anticoagulation therapy 10. Antiplatelet therapy except for aspirin 11. GI ulceration < 60 days before screening visit 12. GI bleeding, perforation, obstruction < 6 months of screening visit 13. Inflammatory bowel disease, diverticulitis active < 6 months of screening visit 14. AST, ALT, or BUN >2x the upper limit normal (within 30 days prior to screening visit) 15. Creatinine level >1.7 mg/dL in men, 1.5 mg/dL in women (within 30 days prior to screening visit) 16. On fluconazole, methotrexate, or lithium therapy 17. Malignancy < 5 years before screening visit 18. Other known, active, significant GI, hepatic, renal, or coagulation disorders 19. Allergy, allergic-type reactions or hypersensitivity (e.g. asthma, urticaria, etc.) to any of the study medications and its components (i.e. sulfonamides) 20. History of any disease of condition that, in the opinion of the investigator would place the subject at an unacceptable risk to participate in this study 21. Any clinically relevant abnormal findings in physical examination, vital signs, or previous laboratory works that, in the opinion of the investigator, may compromise the safety of the subject to participate 22. Subjects who are legally institutionalized 23. Lactating females or females of childbearing potential except for those who are surgically sterile or postmenopausal- |
Country | Name | City | State |
---|---|---|---|
United States | Inova Heart and Vascular Institute | Falls Church | Virginia |
Lead Sponsor | Collaborator |
---|---|
Inova Health Care Services |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Platelet aggregation | Change in platelet aggregation by light transmittance aggregometry between treatment groups | 12 weeks | |
Secondary | Serum TxB2 | Changes in serum TxB2 between treatment groups | 12 weeks | |
Secondary | Urine thromboxane | Changes in urine thromboxane between treatment groups | 12 weeks | |
Secondary | Urine 8 iso prostaglandin | Changes in urine 8 iso prostaglandin between treatment groups | 12 weeks | |
Secondary | Endothelial function by EndoPAT | Changes in endothelial function by EndoPAT (Endothelial Peripheral Arterial Tone) between treatment groups | 12 weeks | |
Secondary | Soluble markers of circulating adhesion molecules (VCAM, ICAM). | Changes in soluble markers of circulating adhesion molecules (VCAM, and ICAM) between treatment groups | 12 weeks | |
Secondary | hsCRP | Changes in hsCRP between treatment groups | 12 weeks | |
Secondary | Oxidized LDL | Changes in Oxidized LDL between treatment groups | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04098172 -
Evaluate the Performance and Safety of Comet Pressure Guidewire in the Measurement of FFR
|
N/A |